Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection. Hit-to-lead and lead optimization beginning with compound 1 established the importance of the C3 and C4 substituent to antiviral potency against viruses with different aa124/aa125 variants of IN. The importance of the C7 position on the serum shifted potency was established. Introduction of a quinoline substituent at the C4 position provided a balance of potency and metabolic stability. Combination of these findings ultimately led to the discovery of compound 26 (BI 224436), the first NCINI to advance into a phase Ia clinical trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although ALLINIs have yet to advance in clinical trials, several compounds display exquisite low-nM potencies to inhibit HIV-1 replication in vitro172,180,182,183.”
From Structure and function of retroviral integrase (2022) · cites this paper as [172]
In the citing paper
“Many ALLINIs were co-crystallised with the isolated HIV-1 IN CCD, and the structures revealed the molecules grip onto the LEDGF/p75 IBD binding pocket at the IN CCD dimerization interface171,172,174,175,180,186,187.”
From Structure and function of retroviral integrase (2022) · cites this paper as [172]
In the citing paper
“Lead compounds in this class were discovered using two very different high-throughput approaches: a screen for inhibitors of HIV-1 IN 3’-processing activity172, and structure-based design of small molecule inhibitors of the HIV-1 IN-LEDGF/p75 interaction171.”
From Structure and function of retroviral integrase (2022) · cites this paper as [172]
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303594200 · Cited by 493
Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479
Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75
Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T., & Engelman, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506924102 · Cited by 408
Jurado, K. A., Wang, H., Slaughter, A., Feng, L., Kessl, J. J., Koh, Y., Wang, W., Ballandras-Colas, A., Patel, P. A., Fuchs, J. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300703110 · Cited by 203
Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors
Kessl, J. J., Jena, N., Koh, Y., Taskent-Sezgin, H., Slaughter, A., Feng, L., de Silva, S., Wu, L., Le Grice, S. F. J., Engelman, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.354373 · Cited by 182
Christ, F., Shaw, S., Demeulemeester, J., Desimmie, B. A., Marchand, A., Butler, S., Smets, W., Chaltin, P., Westby, M., Debyser, Z., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00717-12 · Cited by 176
Research works printed but not linked: 5
- Clavel F., 2004, N. Engl. J. Med., 350, 1023, 10.1056/nejmra025195 · doi:10.1056/nejmra025195 · Paper page
- Arribas J. R., 2013, Curr. Opin. HIV AIDS, 8, 341
- aFenwick, C.; Bethell, R.; Bonneau, P.; Duan, J.; Faucher, A.M.; Mason, S.; Poupart, M.A.; Simoneau, B.; Tsantrizos, Y.; Yoakim, C.Identification of BI-C, a novel HIV-1 non-catalytic site integrase inhibitor.18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 27 February–3 March, 2011 (abstract 523).
- bSimoneau, B.; Amad, M.; Bailey, M. D.; Bethell, R.; Bhardwaj, P. K.; Bilodeau, F.; Bonneau, P.; Bös, M.; Bousquet, Y.; Brochu, C.; Carson, R.; Chabot, C.; Cordingley, M.; Coulombe, R.; Duan, J.; Edwards, P.; Fader, L.; Faucher, A.M.; Fenwick, C.; Garneau, M.; Halmos, T.; Jakalian, A.; Kawai, S.; Landry, S.; Laplante, S.; Malenfant, E.; Mason, S.; Morin, S.; Parisien, M.; Pesant, M.; Poupart, M.A.; Tsantrizos, Y.; Wernic, D.; Yoakim, C.Identification of Novel Non-Catalytic Site Integrase Inhibitors (NCINIs) of LTR DNA 3′ Processing.24th International-Conference on Antiviral Research, Sofia, Bulgaria, May 8–11th, 2011, (Late Breaker abstract).
- Feng L., 2013, J. Biol. Chem., 288, 15813, 10.1074/jbc.m112.443390 · DOI · Paper page
Cited by
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Petta, I., Lievens, S., Libert, C., Tavernier, J., & De Bosscher, K. (2016) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240
Lesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Hindmarsh, P., & Leis, J. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.4.836-843.1999 · Cited by 202
da Cunha, J., Maselli, L. M. F., Stern, A. C. B., Spada, C., & Bydlowski, S. P. (2015) · World Journal of Virology · doi:10.5501/wjv.v4.i2.56 · Cited by 167
Intermolecular Palladium(0)-Catalyzed Atropo-enantioselective C–H Arylation of Heteroarenes
Nguyen, Q.-H., Guo, S., Royal, T., Baudoin, O., & Cramer, N. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12299 · Cited by 165
HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis
Kessl, J. J., Kutluay, S. B., Townsend, D., Rebensburg, S., Slaughter, A., Larue, R. C., Shkriabai, N., Bakouche, N., Fuchs, J. R., Bieniasz, P. D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.044 · Cited by 152
Laraia, L., McKenzie, G., Spring, D. R., Venkitaraman, A. R., & Huggins, D. J. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.04.019 · Cited by 148
Heo, L., Lee, H., & Seok, C. (2016) · Scientific Reports · doi:10.1038/srep32153 · Cited by 142
Structure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
HIV-1 Maturation: Lessons Learned from Inhibitors
Kleinpeter, A. B., & Freed, E. O. (2020) · Viruses · doi:10.3390/v12090940 · Cited by 118
Vranckx, L. S., Demeulemeester, J., Saleh, S., Boll, A., Vansant, G., Schrijvers, R., Weydert, C., Battivelli, E., Verdin, E., Cereseto, A., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.039 · Cited by 113
“In any case LEDGIN treatment results in a steep dose-dependent inhibition of viral replication in cell culture, supporting their clinical development (Fader et al., 2014; Fenwick et al., 2014).”
BackgroundCellular and molecular mechanisms of HIV-1 integration targeting
Engelman, A., & Singh, P. K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2772-5 · Cited by 113
Host factors for retroviral integration site selection
Debyser, Z., Christ, F., Rijck, J. D., & Gijsbers, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.001 · Cited by 102
Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
Fenwick, C., Amad, M., Bailey, M. D., Bethell, R., Bös, M., Bonneau, P., Cordingley, M., Coulombe, R., Duan, J., Edwards, P., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02719-13 · Cited by 99
Self-citationZhang, X., Li, S., Yu, W., Xie, Y., Tung, C., & Xu, Z. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02563 · Cited by 95
Advances in the Catalytic Asymmetric Synthesis of Atropisomeric Hexatomic N‐Heterobiaryls
Cheng, D., & Shao, Y. (2020) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202000354 · Cited by 93
Stereochemistry and Recent Applications of Axially Chiral Organic Molecules
Mancinelli, M., Bencivenni, G., Pecorari, D., & Mazzanti, A. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201901918 · Cited by 87
Enantioselective synthesis of molecules with multiple stereogenic elements
Gaucherand, A., Yen‐Pon, E., Domain, A., Bourhis, A., Rodriguez, J., & Bonne, D. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00238a · Cited by 87
LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014)
Demeulemeester, J., Chaltin, P., Marchand, A., De Maeyer, M., Debyser, Z., & Christ, F. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.898753 · Cited by 83
Shao, Y., & Cheng, D. (2020) · ChemCatChem · doi:10.1002/cctc.202001750 · Cited by 83
Organocatalytic Atroposelective Friedländer Quinoline Heteroannulation
Shao, Y., Dong, M.-M., Wang, Y.-A., Cheng, P., Wang, T., & Cheng, D. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01731 · Cited by 80
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 78
Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor
Fandrick, K. R., Li, W., Zhang, Y., Tang, W., Gao, J., Rodriguez, S., Patel, N. D., Reeves, D. C., Wu, J., Sanyal, S., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201501575 · Cited by 73
Self-citationAsymmetric Synthesis of Quinoline-Naphthalene Atropisomers by Central-to-Axial Chirality Conversion
Wang, S., Wang, Z., Tang, Y. F., Chen, J., & Zhou, L. P. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c03285 · Cited by 70
Allosteric modulation of protein oligomerization: an emerging approach to drug design
Gabizon, R., & Friedler, A. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00009 · Cited by 69
Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase
Gupta, K., Turkki, V., Sherrill-Mix, S., Hwang, Y., Eilers, G., Taylor, L., McDanal, C., Wang, P., Temelkoff, D., Nolte, R. T., et al. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002584 · Cited by 68
Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity.
Hajimahdi, Z., & Zarghi, A. (2016) · PubMed Central · Cited by 68
Miyaji, R., Asano, K., & Matsubara, S. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701707 · Cited by 68
Recent Advances in the Development of Integrase Inhibitors for HIV Treatment
Trivedi, J. S., Mahajan, D., Jaffe, R. J., Acharya, A., Mitra, D., & Byrareddy, S. N. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00480-3 · Cited by 60
Kharisma, V. D., Widyananda, M. H., Ansori, A. N. M., Nege, A. S., Naw, S. W., & Nugraha, A. P. (2021) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres21.1009_9.4.435 · Cited by 59
Hu, S., Chen, J., Cao, J.-X., Zhang, S., Gu, S., & Chen, F.-E. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106549 · Cited by 54
Recent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 Integrase
Choi, E., Mallareddy, J. R., Lu, D., & Kolluru, S. (2018) · Future Science OA · doi:10.4155/fsoa-2018-0060 · Cited by 51
Computational and Artificial Intelligence Techniques for Drug Discovery and Administration
Balasubramanian, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00015-3 · Cited by 50
HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
Koneru, P. C., Francis, A. C., Deng, N., Rebensburg, S. V., Hoyte, A. C., Lindenberger, J., Adu-Ampratwum, D., Larue, R. C., Wempe, M. F., Engelman, A. N., et al. (2019) · eLife · doi:10.7554/elife.46344 · Cited by 49
HIV-1 Integrase Multimerization as a Therapeutic Target
Feng, L., Larue, R. C., Slaughter, A., Kessl, J. J., & Kvaratskhelia, M. (2015) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2015_439 · Cited by 45
Han, X., Wu, H., Wang, W., Dong, C., Tien, P., Wu, S., & Zhou, H. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob01333f · Cited by 45
Wei, Y., Li, W., Du, T., Hong, Z., & Lin, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143572 · Cited by 43
Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery
Yan, X. C., Sanders, J. M., Gao, Y.-D., Tudor, M., Haidle, A. M., Klein, D. J., Converso, A., Lesburg, C. A., Zang, Y., & Wood, H. B. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00113 · Cited by 43
Bonnard, D., Le Rouzic, E., Eiler, S., Amadori, C., Orlov, I., Bruneau, J.-M., Brias, J., Barbion, J., Chevreuil, F., Spehner, D., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816793 · Cited by 42
Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor
Fandrick, K. R., Li, W., Zhang, Y., Tang, W., Gao, J., Rodríguez, S., Patel, N. D., Reeves, D. C., Wu, J., Sanyal, S., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201501575 · Cited by 42
Self-citationMultimodal Functionalities of HIV-1 Integrase
Engelman, A., & Kvaratskhelia, M. (2022) · Viruses · doi:10.3390/v14050926 · Cited by 41
Different Pathways Leading to Integrase Inhibitors Resistance
Thierry, E., Deprez, E., & Delelis, O. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02165 · Cited by 40
Iegre, J., Brear, P., Baker, D. J., Tan, Y. S., Atkinson, E. L., Sore, H. F., O’Donovan, D. H., Verma, C. S., Hyvönen, M., & Spring, D. R. (2019) · Chemical Science · doi:10.1039/c9sc00798a · Cited by 40
Maehigashi, T., Ahn, S., Kim, U.-I., Lindenberger, J. J., Oo, A., Koneru, P. C., Mahboubi, B., Engelman, A., Kvaratskhelia, M., Kim, K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009671 · Cited by 40
Peese, K. M., Allard, C. W., Connolly, T., Johnson, B. L., Li, C., Patel, M., Sorensen, M. E., Walker, M. A., Meanwell, N. A., McAuliffe, B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01473 · Cited by 39
Slaughter, A., Jurado, K. A., Deng, N., Feng, L., Kessl, J. J., Shkriabai, N., Larue, R. C., Fadel, H. J., Patel, P. A., Jena, N., et al. (2014) · Retrovirology · doi:10.1186/s12977-014-0100-1 · Cited by 39
Sugiyama, S., Akiyama, T., Taoda, Y., Iwaki, T., Matsuoka, E., Akihisa, E., Seki, T., Yoshinaga, T., & Kawasuji, T. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127742 · Cited by 39
Zuo, X., Huo, Z., Kang, D., Wu, G., Zhou, Z., Liu, X., & Zhan, P. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1438410 · Cited by 39
Esposito, F., Ambrosio, F. A., Maleddu, R., Costa, G., Rocca, R., Maccioni, E., Catalano, R., Romeo, I., Eleftheriou, P. T., Karia, D. C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111617 · Cited by 38
Carmona, J. A., Rodríguez‐Salamanca, P., Fernández, R., Lassaletta, J. M., & Hornillos, V. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202306981 · Cited by 38
Feng, L., Dharmarajan, V., Serrao, E., Hoyte, A., Larue, R. C., Slaughter, A., Sharma, A., Plumb, M. R., Kessl, J. J., Fuchs, J. R., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00167 · Cited by 37
Zhang, D., Yan, H.-L., Xu, X., Xu, L., Yin, Z., Chang, S., & Luo, H. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1743282 · Cited by 37
Deng, N., Hoyte, A., Mansour, Y. E., Mohamed, M. S., Fuchs, J. R., Engelman, A. N., Kvaratskhelia, M., & Levy, R. (2016) · Protein Science · doi:10.1002/pro.2997 · Cited by 36
Balasubramanian, K., & Gupta, S. P. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304152704 · Cited by 36
Indole-based allosteric inhibitors of HIV-1 integrase
Patel, P. A., Kvaratskhelia, N., Mansour, Y. E., Antwi, J., Feng, L., Koneru, P. C., Kobe, M. J., Jena, N., Shi, G., Mohamed, M. S., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.037 · Cited by 36
GS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell Culture
Bruggemans, A., Vansant, G., Balakrishnan, M., Mitchell, M. L., Cai, R., Christ, F., & Debyser, Z. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02328-20 · Cited by 35
Guo, L., Meanwell, N. A., Krystal, M., Langley, D. R., Naidu, B. N., Sivaprakasam, P., Lewis, H. A., Kish, K., Khan, J., Ng, A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01681 · Cited by 35
Madison, M. K., Lawson, D. Q., Elliott, J., Ozantürk, A. N., Koneru, P. C., Townsend, D., Errando, M., Kvaratskhelia, M., & Kutluay, S. B. (2017) · Journal of Virology · doi:10.1128/jvi.00821-17 · Cited by 34
Exploring the Free-Energy Landscape and Thermodynamics of Protein-Protein Association
Tse, C., Wickstrom, L., Kvaratskhelia, M., Gallicchio, E., Levy, R. M., & Deng, N. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.08.005 · Cited by 34
Shao, Y., Han, D., Dong, M.-M., Yang, X., & Cheng, D. (2020) · Organic Chemistry Frontiers · doi:10.1039/d0qo01339k · Cited by 33
Dynamic Kinetic Reductive Grignard-Type Addition for the Construction of Axial and Central Chirality
Shao, Y.-P., & Liang, Y. (2025) · ACS Catalysis · doi:10.1021/acscatal.4c07172 · Cited by 32
Synthesis and Evaluation of Aryl Quinolines as HIV-1 Integrase Multimerization Inhibitors
Jentsch, N. G., Hart, A. P., Hume, J. D., Sun, J., McNeely, K. A., Lama, C., Pigza, J. A., Donahue, M. G., & Kessl, J. J. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00269 · Cited by 32
Farouk, F., & Shamma, R. N. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201800213 · Cited by 31
Coto‐Cid, J. M., de Gonzalo, G., Carmona, J. A., Iglesias‐Sigüenza, J., Rodríguez‐Salamanca, P., Fernández, R., Hornillos, V., & Lassaletta, J. M. (2023) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202301310 · Cited by 31
Shkriabai, N., Dharmarajan, V., Slaughter, A., Kessl, J. J., Larue, R. C., Feng, L., Fuchs, J. R., Griffin, P. R., & Kvaratskhelia, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589572 · Cited by 30
Hoyte, A. C., Jamin, A. V., Koneru, P. C., Kobe, M. J., Larue, R. C., Fuchs, J. R., Engelman, A. N., & Kvaratskhelia, M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816645 · Cited by 30
Haddad, N., Mangunuru, H. P. R., Fandrick, K. R., Qu, B., Sieber, J. D., Rodríguez, S., Desrosiers, J., Patel, N. D., Lee, H., Kurouski, D., et al. (2016) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201600889 · Cited by 30
Patel, D., Antwi, J., Koneru, P. C., Serrao, E., Forli, S., Kessl, J. J., Feng, L., Deng, N., Levy, R. M., Fuchs, J. R., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753384 · Cited by 30
Rashamuse, T. J., Harrison, A. T., Mosebi, S., van Vuuren, S. F., Coyanis, E. M., & Bode, M. L. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115210 · Cited by 30
Kumar, D., Sharma, P., Shabu, Kaur, R., Lobe, M. M. M., Gupta, G. K., & Ntie‐Kang, F. (2021) · RSC Advances · doi:10.1039/d0ra10655k · Cited by 28
Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs
Fader, L. D., Bailey, M., Beaulieu, E., Bilodeau, F., Bonneau, P., Bousquet, Y., Carson, R. J., Chabot, C., Coulombe, R., Duan, J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00194 · Cited by 26
Self-citationUse of Integrase Inhibitors in HIV-Infected Children and Adolescents
Dehority, W. N., Abadi, J., WIZNIA, A. A., & Viani, R. M. (2015) · Drugs · doi:10.1007/s40265-015-0446-2 · Cited by 26
Cruz, J., Wickstrom, L., Yang, D., Gallicchio, E., & Deng, N. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b01119 · Cited by 26
Zhang, X., Liu, H., & Jia, Y. (2016) · Chemical Communications · doi:10.1039/c6cc02600a · Cited by 26
Investigational HIV integrase inhibitors in phase I and phase II clinical trials
Han, Y.-S., Mésplède, T., & Wainberg, M. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1378643 · Cited by 24
Azzman, N., Gill, M. S. A., Hassan, S. S., Christ, F., Debyser, Z., Mohamed, W. A. S., & Ahemad, N. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2529 · Cited by 24
Esposito, F., Sechi, M., Pala, N., Sanna, A., Koneru, P. C., Kvaratskhelia, M., Naesens, L. M. J., Corona, A., Grandi, N., Santo, R. D., et al. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104671 · Cited by 24
Fader, L. D., Carson, R. J., Morin, S., Bilodeau, F., Chabot, C., Halmos, T., Bailey, M. D., Kawai, S. H., Coulombe, R., LaPlante, S. R., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500110j · Cited by 24
Self-citationJentsch, N. G., Hume, J. D., Crull, E. B., Beauti, S. M., Pham, A. H., Pigza, J. A., Kessl, J. J., & Donahue, M. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.229 · Cited by 24
Retroviral integrase: Structure, mechanism, and inhibition
Passos, D. O., Li, M., Craigie, R., & Lyumkis, D. (2021) · The Enzymes · doi:10.1016/bs.enz.2021.06.007 · Cited by 22
The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function
Singer, M. R., Dinh, T., Levintov, L., Annamalai, A. S., Rey, J. S., Briganti, L., Cook, N., Pye, V. E., Taylor, I. A., Kim, K., et al. (2023) · mBio · doi:10.1128/mbio.03560-22 · Cited by 21
Shao, Y., Han, D., Ma, W., & Cheng, D. (2020) · Organic Chemistry Frontiers · doi:10.1039/d0qo00534g · Cited by 21
Exploring HIV-1 Maturation: A New Frontier in Antiviral Development
McGraw, A., Hillmer, G., Mehedincu, S. M., Hikichi, Y., Gagliardi, S., Narayan, K., Tibebe, H., Marquez, D., Bose, L. M., Keating, A., et al. (2024) · Viruses · doi:10.3390/v16091423 · Cited by 19
Hao, X., Wang, B., Tian, Z., Yao, Z., Qiao, T., Huang, L., & Fu, H. (2025) · Organic Chemistry Frontiers · doi:10.1039/d5qo00011d · Cited by 19
CLIP-related methodologies and their application to retrovirology
Bieniasz, P. D., & Kutluay, S. B. (2018) · Retrovirology · doi:10.1186/s12977-018-0417-2 · Cited by 19
Zhou, X., Sun, Y., Dai, J., Xu, J., & Xu, H. (2017) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2017.09.037 · Cited by 19
Abrusán, G., & Marsh, J. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00220 · Cited by 19
Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase
Bonnard, D., Rouzic, E. L., Singer, M. R., Yu, Z., Strat, F. L., Batisse, C., Batisse, J., Amadori, C., Chasset, S., Pye, V. E., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-23 · Cited by 17
Chemical and ribosomal synthesis of atropisomeric and macrocyclic peptides with embedded quinolines
Knudson, I. J., Dover, T. L., Dilworth, D. A., Paloutzian, C., Paz, O., Lin, J., Cho, H. Y., Gonen, T., Schepartz, A., & Miller, S. J. (2025) · Nature Chemistry · doi:10.1038/s41557-025-01935-4 · Cited by 17
Targeting Virus-host Interactions of HIV Replication
Weydert, C., Rijck, J. D., Christ, F., & Debyser, Z. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150901115106 · Cited by 17
Implications of Fragment-Based Drug Discovery in Tuberculosis and HIV
Mallakuntla, M. K., Togre, N. S., Santos, D. B., & Tiwari, S. (2022) · Pharmaceuticals · doi:10.3390/ph15111415 · Cited by 17
1,2-Dibenzoylhydrazine as a Multi-Inhibitor Compound: A Morphological and Docking Study
Patamia, V., Floresta, G., Zagni, C., Pistarà, V., Punzo, F., & Rescifina, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021425 · Cited by 17
HIV-1 integrase binding to genomic RNA 5′-UTR induces local structural changes in vitro and in virio
Liu, S., Koneru, P. C., Li, W., Pathirage, C., Engelman, A., Kvaratskhelia, M., & Musier‐Forsyth, K. (2021) · Retrovirology · doi:10.1186/s12977-021-00582-0 · Cited by 16
Zhang, F.-H., Debnath, B., Xu, Z.-L., Yang, L.-M., Song, L.-R., Zheng, Y., Neamati, N., & Long, Y. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.045 · Cited by 16
Inhibitors of the integrase–transportin-SR2 interaction block HIV nuclear import
Demeulemeester, J., Blokken, J., Houwer, S. D., Dirix, L., Klaassen, H., Marchand, A., Chaltin, P., Christ, F., & Debyser, Z. (2018) · Retrovirology · doi:10.1186/s12977-018-0389-2 · Cited by 15
Enantioselective synthesis of 3-( N -indolyl)quinolines containing axial and central chiralities
Yamanomoto, K., Yamamoto, K., Yoshida, S., Sato, S., & Akiyama, T. (2023) · Chemical Communications · doi:10.1039/d3cc05142k · Cited by 14
Dinh, T., Tber, Z., Rey, J. S., Mengshetti, S., Annamalai, A. S., Haney, R., Briganti, L., Amblard, F., Fuchs, J. R., Cherepanov, P., et al. (2024) · mBio · doi:10.1128/mbio.00465-24 · Cited by 14
Burlein, C., Wang, C., Xu, M., Bhatt, T., Stahlhut, M. W., Ou, Y., Adam, G. C., Heath, J., Klein, D. J., Sanders, J. M., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00550 · Cited by 14
Optimized binding of substituted quinoline ALLINIs within the HIV-1 integrase oligomer
Sun, J., Patel, K., Hume, J. D., Pigza, J. A., Donahue, M. G., & Kessl, J. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100363 · Cited by 14
Metadata
- Authors
- Fader, L. D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., Halmos, T., Bousquet, Y., Bailey, M. D., Kawai, S. H., Coulombe, R., LaPlante, S., Jakalian, A., Bhardwaj, P. K., Wernic, D., Schroeder, P., Amad, M., Edwards, P., Garneau, M., Duan, J., Cordingley, M., Bethell, R., Mason, S. W., Bös, M., Bonneau, P., Poupart, M.-A., Faucher, A.-M., Simoneau, B., Fenwick, C., Yoakim, C., & Tsantrizos, Y.
- Affiliations
- Boehringer Ingelheim (Canada) (CA)
- Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval, Québec H7S 2G5, Canada
- Corresponding author
- Fader, Lee D.
- ORCID
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-01-28
- Volume
- 5
- Issue
- 4
- Pages
- 422-427
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4027581
- OpenAlex
- W2000546717
- Cited by
- 178
- References
- 23
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 13 · 2023: 15 · 2022: 12 · 2021: 15 · 2020: 19 · 2019: 17 · 2018: 12 · 2017: 10 · 2016: 20 · 2015: 11 · 2014: 9
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- HIV-1 integrase, antiviral drug discovery, hit-to-lead optimization, metabolic stability, lead optimization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.